Saar I Gill, MD, PhD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations

Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-4015
Lab: (215) 573-4015
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent link

Description of Research Expertise

Tumor Immunology
Chimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry

Selected Publications

Cummins KD*, Frey N*, Nelson AM*, Schmidt A*, Luger S, Isaacs RE*, Lacey SF, Hexner E, Melenhorst JJ, June CH, Porter DL, Gill SI. : Treating Relapsed / Refractory (RR) AML with Biodegradable AntiCD123 CAR Modified T Cells American Society for Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Poster Presentation"

Ruella M*, Maude SL*, Engels B*, Barrett DM*, Frey N*, Marcucci K,Shestova O, Singh N, Perazzelli J, Christian DA, Hunter CA, Haagen D, Lacey S, Melenhorst J, Brogdon J, Young R, Porter DL, June CH, Grupp S, Gill S.: Clinical efficacy of anti-CD22 chimeric antigen receptor T cells for B-cell acute lymphoblastic leukemia is correlated with the length of the scFv linker and can be predicted using xenograft models. American Society for Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Oral Presentation"

Ruella M, Xu J, Barrett DM*, Kulikovskaya I*, Ambrose DE*, Patel PR*, Reich T*, Scholler J*, Nazimuddin F*, Fraietta JA*, Maude SL, Gill SI, Levine BL, Nobles CL*, Bushman FD*, Orlando E*, Grupp SA, June CH, Melenhorst JJ, Lacey SF.: Iatrogenic Induction of Chimeric Antigen Receptor Therapy Resistance American Society of Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Poster Presentation"

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S: Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery 7(10): 1154-67, Oct 2017 Notes: doi: 10.1158/2159-8290.

Gill SI*, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Hwang W, June CH, Porter DL.: Combination of humanized CD19-targeted chimeric antigen receptor T cells with ibrutinib in adults with chronic lymphocytic leukemia American Society of Clinical Oncology Annual Meeting, Chicago, IL Jun 2017 Notes: "Oral Presentation"

Tasian Sarah K, Kenderian Saad S, Shen Feng, Ruella Marco, Shestova Olga, Kozlowski Miroslaw, Li Yong, Schrank-Hacker April, Morrissette Jennifer J D, Carroll Martin, June Carl H, Grupp Stephan A, Gill Saar: Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 129(17): 2395-2407, Apr 2017.

Glisovic-Aplenc Tina, Gill Saar, Spruce Lynn A, Smith Ian R, Fazelinia Hossein, Shestova Olga, Ding Hua, Tasian Sarah K, Aplenc Richard, Seeholzer Steven H: Improved surfaceome coverage with a label-free nonaffinity-purified workflow. Proteomics 17(7), Apr 2017 Notes: Epub ahead of print Mar 6 2017.

Gill Saar: Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy. Science translational medicine 9(375), Feb 2017 Notes: pii eaam6051.

Gill Saar: CAR T cells engage in anticancer martial arts. Science translational medicine 9(373), Jan 2017 Notes: piieaal4996.

Gill Saar: Chimeric antigen receptor T cell therapy in AML: How close are we? Best practice & research. Clinical haematology 29(4): 329-333, Dec 2016.

back to top
Last updated: 10/25/2017
The Trustees of the University of Pennsylvania